Toolkit/Pyr-NHS-functionalised 3D graphene foam electrode biosensor

Pyr-NHS-functionalised 3D graphene foam electrode biosensor

Construct Pattern·Research·Since 2025

Also known as: 3D graphene foam-based biosensor, Pyr-NHS-functionalised 3D graphene foam electrodes

Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

we developed assays on three-dimensional (3D) graphene foam electrodes by functionalising them with a 1-Pyrenebutyric acid N-hydroxysuccinimide ester (Pyr-NHS) to enable effective antibody immobilisation for the detection of amyloid beta peptides (Aβ42 and Aβ40)

Usefulness & Problems

Why this is useful

This biosensor uses Pyr-NHS-functionalised 3D graphene foam electrodes to immobilise antibodies and electrochemically detect Aβ42 and Aβ40. The abstract presents it as a sensitive and specific assay platform for Alzheimer's disease biomarker detection.; electrochemical detection of Aβ42; electrochemical detection of Aβ40; point-of-care biosensing for Alzheimer's disease biomarkers

Source:

This biosensor uses Pyr-NHS-functionalised 3D graphene foam electrodes to immobilise antibodies and electrochemically detect Aβ42 and Aβ40. The abstract presents it as a sensitive and specific assay platform for Alzheimer's disease biomarker detection.

Source:

electrochemical detection of Aβ42

Source:

electrochemical detection of Aβ40

Source:

point-of-care biosensing for Alzheimer's disease biomarkers

Problem solved

It addresses the need for more cost-effective, portable, and less complex point-of-care detection of Alzheimer's disease biomarkers.; provides a sensitive electrochemical platform for detecting AD biomarkers; supports antibody immobilisation on graphene foam electrodes

Source:

It addresses the need for more cost-effective, portable, and less complex point-of-care detection of Alzheimer's disease biomarkers.

Source:

provides a sensitive electrochemical platform for detecting AD biomarkers

Source:

supports antibody immobilisation on graphene foam electrodes

Problem links

provides a sensitive electrochemical platform for detecting AD biomarkers

Literature

It addresses the need for more cost-effective, portable, and less complex point-of-care detection of Alzheimer's disease biomarkers.

Source:

It addresses the need for more cost-effective, portable, and less complex point-of-care detection of Alzheimer's disease biomarkers.

supports antibody immobilisation on graphene foam electrodes

Literature

It addresses the need for more cost-effective, portable, and less complex point-of-care detection of Alzheimer's disease biomarkers.

Source:

It addresses the need for more cost-effective, portable, and less complex point-of-care detection of Alzheimer's disease biomarkers.

Published Workflows

Electrochemical Detection of Aβ42 and Aβ40 at Attomolar Scale via Optimised Antibody Loading on Pyr-NHS-Functionalised 3D Graphene Foam Electrodes.

2025

Objective: Develop a point-of-care electrochemical biosensing assay for sensitive detection of Alzheimer's disease biomarkers Aβ42 and Aβ40 using Pyr-NHS-functionalised 3D graphene foam electrodes.

Why it works: The abstract attributes performance to stable Pyr-NHS functionalisation, the superior conductivity and larger surface area of 3D graphene foam, and optimisation of antibody concentration for immobilisation.

stable antibody immobilisation via Pyr-NHS functionalisationreduced non-specific binding via BSA blockingenhanced electrochemical performance via conductive high-surface-area 3D graphene foamsurface functionalisationantibody immobilisationelectrochemical DPV readoutinterference testingspiked plasma validation

Stages

  1. 1.
    Electrode functionalisation and assay assembly(library_build)

    This stage creates the functional biosensor surface needed for analyte detection.

    Selection: Functionalise 3D graphene foam electrodes with Pyr-NHS, bind Aβ42 and Aβ40 antibodies, and block with BSA to create the assay surface.

  2. 2.
    Electrochemical performance measurement(functional_characterization)

    This stage quantifies whether the assembled biosensor performs adequately for Aβ42 and Aβ40 detection.

    Selection: Use DPV to measure stability and analyte detection performance.

  3. 3.
    Interference assessment(counter_screen)

    This stage checks whether the biosensor signal is affected by a related non-target biomarker.

  4. 4.
    Spiked plasma validation(confirmatory_validation)

    This stage tests whether the biosensor retains utility in a more realistic biological sample matrix than buffer-only measurements.

    Selection: Validate assay performance in spiked-diluted human plasma.

Steps

  1. 1.
    Functionalise 3D graphene foam electrodes with Pyr-NHSelectrode substrate and surface linker

    Enable effective and stable antibody immobilisation on the electrode surface.

    Surface functionalisation is performed first because it prepares the graphene foam for subsequent antibody binding.

  2. 2.
    Bind Aβ42 and Aβ40 antibodies to the functionalised electrodecapture interface assembly

    Create analyte-specific recognition surfaces for Aβ42 and Aβ40 detection.

    Antibody binding follows Pyr-NHS functionalisation because the linker chemistry is used to enable antibody immobilisation.

  3. 3.
    Block the electrode surface with BSAblocking reagent

    Minimise non-specific binding on the electrode surface.

    Blocking is performed after antibody immobilisation to reduce non-specific interactions before measurement.

  4. 4.
    Measure biosensor performance by DPVbiosensor under test and readout method

    Assess stability and detection performance for Aβ42 and Aβ40.

    Electrochemical measurement is performed after assay assembly because the completed biosensor must be read out to determine performance.

  5. 5.
    Test interference from tau217 proteinbiosensor under specificity challenge

    Evaluate whether a non-target AD-related protein interferes with Aβ detection.

    Interference testing follows primary performance measurement to check specificity after sensitive detection has been established.

  6. 6.
    Validate the biosensor in spiked-diluted human plasmabiosensor under matrix validation

    Confirm assay function in a human plasma matrix.

    Plasma validation is performed after analytical characterization to test whether the assay remains usable in a more realistic sample matrix.

Taxonomy & Function

Primary hierarchy

Mechanism Branch

Architecture: A reusable architecture pattern for arranging parts into an engineered system.

Target processes

No target processes tagged yet.

Input: Chemical

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor

The assay requires 3D graphene foam electrodes, Pyr-NHS linker chemistry, antibodies against Aβ42 and Aβ40, BSA as a blocking agent, and DPV readout.; requires Pyr-NHS surface functionalisation; requires Aβ42 and Aβ40 antibodies; requires BSA blocking to minimise non-specific binding; requires DPV electrochemical measurement

The abstract does not show direct clinical diagnostic performance in unspiked patient samples, only validation in spiked-diluted human plasma.; validation described in the abstract is limited to spiked-diluted human plasma

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Supporting Sources

Ranked Claims

Claim 1analytical sensitivitysupports2025Source 1needs review

The biosensor achieved attomolar-scale limits of detection of 252 aM for Aβ42 and 395 aM for Aβ40.

The biosensor exhibited a low limit of detection (LOD) with 252 aM for Aβ42 and 395 aM for Aβ40
limit of detection for Aβ40 395 aMlimit of detection for Aβ42 252 aM
Claim 2dynamic rangesupports2025Source 1needs review

The biosensor covered a 0.125 fM-1 nM linear range for Aβ42 and a 0.125 fM-100 pM linear range for Aβ40.

covering 0.125 fM-1 nM and 0.125 fM-100 pM linear ranges, respectively
linear range for Aβ40 0.125 fM-100 pMlinear range for Aβ42 0.125 fM-1 nM
Claim 3mechanistic attributionsupports2025Source 1needs review

The reported analytical performance was attributed to stable Pyr-NHS functionalisation, the superior conductivity and larger surface area of 3D graphene foam, and optimisation of antibody concentration for immobilisation.

This excellent analytical performance was attributed to the stable Pyr-NHS functionalisation, the 3D graphene foam enabling superior conductivity and a larger surface area on the working electrode, and the optimisation of antibody concentration for immobilisation.
Claim 4stabilitysupports2025Source 1needs review

DPV measurements showed satisfactory biosensor stability over 12 days with RDS upper limit below 10%.

Differential Pulse Voltammetry (DPV) measurements showed satisfactory stability over 12 days (RDS upper limit was <10%)
RDS upper limit 10 %stability duration 12 days
Claim 5tool performancesupports2025Source 1needs review

A Pyr-NHS-functionalised 3D graphene foam electrode biosensor enabled highly sensitive and specific electrochemical detection of Aβ42 and Aβ40.

Differential Pulse Voltammetry (DPV) measurements showed satisfactory stability over 12 days (RDS upper limit was <10%) and highly sensitive and specific detection of Aβ42 and Aβ40, with insignificant interference of tau217 protein.

Approval Evidence

1 source5 linked approval claimsfirst-pass slug pyr-nhs-functionalised-3d-graphene-foam-electrode-biosensor
we developed assays on three-dimensional (3D) graphene foam electrodes by functionalising them with a 1-Pyrenebutyric acid N-hydroxysuccinimide ester (Pyr-NHS) to enable effective antibody immobilisation for the detection of amyloid beta peptides (Aβ42 and Aβ40)

Source:

analytical sensitivitysupports

The biosensor achieved attomolar-scale limits of detection of 252 aM for Aβ42 and 395 aM for Aβ40.

The biosensor exhibited a low limit of detection (LOD) with 252 aM for Aβ42 and 395 aM for Aβ40

Source:

dynamic rangesupports

The biosensor covered a 0.125 fM-1 nM linear range for Aβ42 and a 0.125 fM-100 pM linear range for Aβ40.

covering 0.125 fM-1 nM and 0.125 fM-100 pM linear ranges, respectively

Source:

mechanistic attributionsupports

The reported analytical performance was attributed to stable Pyr-NHS functionalisation, the superior conductivity and larger surface area of 3D graphene foam, and optimisation of antibody concentration for immobilisation.

This excellent analytical performance was attributed to the stable Pyr-NHS functionalisation, the 3D graphene foam enabling superior conductivity and a larger surface area on the working electrode, and the optimisation of antibody concentration for immobilisation.

Source:

stabilitysupports

DPV measurements showed satisfactory biosensor stability over 12 days with RDS upper limit below 10%.

Differential Pulse Voltammetry (DPV) measurements showed satisfactory stability over 12 days (RDS upper limit was <10%)

Source:

tool performancesupports

A Pyr-NHS-functionalised 3D graphene foam electrode biosensor enabled highly sensitive and specific electrochemical detection of Aβ42 and Aβ40.

Differential Pulse Voltammetry (DPV) measurements showed satisfactory stability over 12 days (RDS upper limit was <10%) and highly sensitive and specific detection of Aβ42 and Aβ40, with insignificant interference of tau217 protein.

Source:

Comparisons

Source-stated alternatives

The source contrasts this platform with conventional diagnostic methods that are expensive, time-consuming, and highly complex.

Source:

The source contrasts this platform with conventional diagnostic methods that are expensive, time-consuming, and highly complex.

Source-backed strengths

attomolar-scale limits of detection for Aβ42 and Aβ40; reported specificity with insignificant interference from tau217 protein; 12-day stability with RDS upper limit below 10%; 3D graphene foam provides superior conductivity and larger surface area

Source:

attomolar-scale limits of detection for Aβ42 and Aβ40

Source:

reported specificity with insignificant interference from tau217 protein

Source:

12-day stability with RDS upper limit below 10%

Source:

3D graphene foam provides superior conductivity and larger surface area

Compared with bacterial degrons

Pyr-NHS-functionalised 3D graphene foam electrode biosensor and bacterial degrons address a similar problem space.

Shared frame: same top-level item type; same primary input modality: chemical

Compared with MHCK7

Pyr-NHS-functionalised 3D graphene foam electrode biosensor and MHCK7 address a similar problem space.

Shared frame: same top-level item type; same primary input modality: chemical

Compared with rM3Ds

Pyr-NHS-functionalised 3D graphene foam electrode biosensor and rM3Ds address a similar problem space.

Shared frame: same top-level item type; same primary input modality: chemical

Ranked Citations

  1. 1.
    StructuralSource 1MED2025Claim 1Claim 2Claim 3

    Extracted from this source document.